StockMirror — Stock Screener

INDOCO Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Indoco Remedies reported Q2 FY27 consolidated revenue of Rs. 5,069 million, up 7.4% YoY, crossing the Rs. 500 crore milestone for the first time. Growth was driven by international formulations (+12.1%), particularly regulated markets (+21.1%), while domestic formulations declined 5.9% due to weak acute therapies. EBITDA margin was 9.2% (flat YoY, down QoQ), impacted by higher material costs and Rs. 13 crore freight cost increase. Management maintained domestic high single-digit growth guidance and expects decent double-digit international growth. Key headwinds include USFDA observations at Goa plant (decision by December), ophthal portfolio divestment impact (Rs. 10-12 crore), and geopolitical cost pressures. Management remains optimistic on long-term growth, with infrastructure capable of 4X current international topline.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized both growth and margins. They highlighted strong revenue growth (crossing Rs. 500 crore) while also focusing on operational efficiencies, cost management, and improving profitability. They are investing in R&D and new products for future growth while controlling costs (R&D capp

About Indoco Remedies Limited

Indoco Remedies Limited (INDOCO) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More